Welcome to our dedicated page for MANNKIND SEC filings (Ticker: MNKD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MANNKIND's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MANNKIND's regulatory disclosures and financial reporting.
MannKind Corp reports that Dominic Marasco, President of the Endocrine Business Unit, had 3,623 shares of common stock withheld on July 15, 2026 at $4.09 per share as a tax-withholding disposition related to the vesting of previously reported restricted stock units under Rule 16b-3. Following this transaction, he directly holds 343,398 shares, including 2,775 shares acquired through the Employee Stock Purchase Plan on June 30, 2026.
MannKind Corp Chief People & Workpl Officer Stuart A. Tross had a previously granted performance restricted stock unit award vest on July 15, 2026, delivering 93,790 shares of common stock. To cover taxes, a total of 65,808 shares were withheld at $4.09 per share, and his direct holdings include shares acquired through the Employee Stock Purchase Plan.
MannKind Corp reports that CEO Michael Castagna had a performance-based restricted stock unit award granted on May 25, 2023 vest on July 15, 2026, delivering 350,260 common shares after achieving 83% of target performance. The original 422,000-unit grant left 71,740 units forfeited. On the same date, an aggregate 363,200 shares of common stock were withheld or delivered at $4.09 per share to satisfy exercise price or tax obligations related to equity awards.
MannKind Corp EVP Technical Operations Sanjay R. Singh reported vesting of a performance-based restricted stock unit award granted in May 2023, delivering 70,550 common shares on July 15, 2026. Footnotes state performance goals were achieved at 83% of target, with 14,450 units forfeited. To satisfy tax obligations, 46,795 shares were withheld at $4.09 per share and characterized as payments of tax liability by delivering or withholding shares under Rule 16b-3. Each restricted stock unit represented one share of common stock.
David Thomson, EVP, General Counsel & Secretary of MannKind, acquired 93,790 shares of common stock on July 15, 2026 through vesting of a performance RSU award, while 19,210 shares were forfeited under the plan. To cover taxes, 98,426 shares were withheld at about $4.09 per share. On July 17, he sold 24,109 shares at a weighted average of $4.05 under a Rule 10b5-1 plan established December 2, 2025, leaving 797,554 shares held directly.
MannKind Corp director Steven B. Binder reported multiple equity transactions. On July 15, 2026, a performance RSU award granted in 2023 vested at 83% of target, delivering 93,790 shares and forfeiting 19,210. Shares totaling 24,395 were withheld to cover taxes. On July 17, 2026, he sold 52,485 shares of common stock at a weighted average price of $4.06, in open-market transactions under a Rule 10b5-1 plan established December 2, 2025. After these transactions, he directly holds 824,918 shares of MannKind common stock.
MannKind Corporation common stock is the subject of a planned sale by an insider, with up to 24,109 shares to be sold through Morgan Stanley Smith Barney LLC on NASDAQ on or about July 17, 2026. The shares have an indicated aggregate market value of $97,400.36, with 308,950,166 shares of common stock outstanding.
The insider recently received 11,462 Restricted Stock Units and 12,647 Performance Stock Units from the issuer on July 15, 2026. The notice also references prior Rule 10b5-1 sales of 3,033 shares of common stock on May 12, 2026 for $9,984.03.
MNKD received a notice of proposed stock sales under Rule 144. A broker intends to sell 52,485 shares of common stock on or after July 17, 2026 on NASDAQ, with an approximate market value of $212,039.40. The shares relate to restricted stock units acquired from the issuer on July 15, 2026. The filing also lists a prior 10b5-1 sale for Steven Binder of 16,940 shares of common stock on May 12, 2026 for proceeds of $55,766.48.
MannKind Corporation reported that the U.S. Food and Drug Administration approved Afrezza (insulin human) Inhalation Powder for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes. This expands Afrezza’s use beyond adults into the pediatric diabetes population.
The FDA also stated that the supplemental biologics license application for this pediatric indication has fulfilled the last remaining postmarketing requirement for Afrezza from its original June 27, 2014 approval. This means all originally required follow-up obligations for Afrezza have now been completed.
MannKind Corporation reports a key regulatory change and a pediatric clinical update for its inhaled insulin Afrezza. The FDA has released the company from a postmarketing requirement to run a five-year, randomized trial in 8,000-10,000 adults with type 2 diabetes to assess pulmonary malignancy risk versus standard care. The only remaining postmarketing requirement for Afrezza is a study of efficacy and safety in pediatric patients.
The FDA is reviewing a supplemental Biologics License Application for Afrezza use in children and adolescents aged 4-17 with a PDUFA target action date of May 29, 2026. MannKind is also enrolling the INHALE-1st study in youth aged 10-17 with newly diagnosed type 1 diabetes, following up to 100 participants across 10 sites for 13 weeks, with an optional 26-week extension, and expects data in late 2027.